Investigating the Effect of Nigella Sativa in Male Genital Wart

Investigating the Therapeutic Effect of Nigella Sativa in Male Genital Wart: A Randomized, Double-Blind Clinical Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20251103067866N1

Enrollment

Registered

2026-01-25

Start date

2026-04-20

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genital Wart. Anogenital (venereal) warts

Interventions

Intervention 1: The intervention group applies imiquimod 5% topically three times per week on alternate nights before bedtime. The application area is washed with soap and water approximately 8 hours

Eligibility

Sex/Gender

Male

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 18 -60 male No past history of immune suppressive disease No concurrent sexually transmitted diseases Genital warts <1 cm diameter No prior human papillomavirus vaccination

Exclusion criteria

Exclusion criteria: People with a history of allergy to Nigella Sativa

Design outcomes

Primary

Measure	Time frame
Size of warty lesions. Timepoint: Before and after the completion of the intervention. Method of measurement: The primary outcome is assessed clinically and documented by measuring size changes using a ruler.;Number of warty lesions. Timepoint: Before and after the completion of the intervention. Method of measurement: Lesions are observed and counted through clinical examination.;Side effects. Timepoint: Before the intervention and 2 weeks after the completion of the intervention. Method of measurement: Yellow form for reporting adverse drug reactions.	—

Measure

Time frame

Size of warty lesions. Timepoint: Before and after the completion of the intervention. Method of measurement: The primary outcome is assessed clinically and documented by measuring size changes using a ruler.;Number of warty lesions. Timepoint: Before and after the completion of the intervention. Method of measurement: Lesions are observed and counted through clinical examination.;Side effects. Timepoint: Before the intervention and 2 weeks after the completion of the intervention. Method of measurement: Yellow form for reporting adverse drug reactions.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMozaffar Rezvani Zadeh

Iran University of Medical Sciences

mozaffar.rezvani.72@gmail.com+98 21 5597 3051

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026